ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE: CLASS 4 CAUTION IN USE

13th August 2020

Class 4 Caution in Use on SmofKabiven extra Nitrogen Electrolyte Free

Fresenius Kabi Ltd & Calea UK Ltd has informed us of an error on the bag labels for SmofKabiven extra nitrogen electrolyte free, emulsion for infusion PL 08828/0269. A sentence has been inadvertently included stating "with electrolytes" on an electrolyte free product. The outer cartons and leaflets have been checked and these are all in compliance. The bag label should state "1. Amino acid solution.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
Alliance do not stockSmofKabiven extra Nitrogen Electrolyte FreeFresenius Kabi Ltd & Calea UK Ltd10NI3300
10PB8836

Alliance healthcare do not stock this product and as this is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Medical.Information-UK@fresenius-kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

10th August 2020

Class 2 Recall on Phosphates Solution For Infusion 500ml

Huddersfield Pharmacy Specials (HPS) is recalling the above batches of phosphates solution for infusion due to observation of precipitation in batch 500609X. The decision to recall all other batches has been made as a precautionary measure.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
Alliance do not stockPhosphates Solution For Infusion 500mlHuddersfield Pharmacy Specials (HPS)Please follow the above link

Alliance Healthcare do not stock this line therefore we will not be accepting customer returns.

For stock control queries please contact: HPS Customer Services, 01484 355388.

For any medical information enquires please contact: Dr Burrinder Grewal, 01484 355230.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

04th August 2020

Class 2 Recall on Clexane 4,000 Iu (40mg) /0.4ml Syringes

Pharmaram Ltd has informed us that the below batch of Clexane 4,000IU (40mg)/0.4ml syringes has an error on the labelling affixed to the plastic blister packaging encasing the syringe. The label incorrectly states "Clexane 6,000IU (60mg)/0.6ml Syringes", when it should have stated "Clexane 4,000IU (40mg)/0.4ml Syringes". The outer carton states the correct strength; the batch number and expiry dates are also correct and match the details on the labelling.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
8129165PI CLEXANE PFS 40MGPHARMARAM LTDCCL67G/D3

For stock control queries please contact:Pharmaram Ltd Austin Chambers Email: austin@dixpharm.com Tel: +44 (0) 1530 410920 Mob: +44 (0) 7944 664400

For any medical information enquires please contact: Pharmaram Ltd Email: quality@dixpharm.com Tel: +44 (0) 1530 410920

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

03rd August 2020

Class 4 Caution in Use on SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

Crescent Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the below batches is missing important safety relevant text changes.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch

4091625SYRENIRING 0.12MG/0.015MG 24 HRCRESCENT PHARMA LTDLF18276AA
LF18894AA

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns.


For more information or medical information queries, please contact: Crescent Pharma Ltd. Medical Information Department on +00351 214643225, via email on tiago.barca@pharsolution.com or +44 (0) 1256 772740.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

03rd August 2020

Class 3 Recall on Digoxin Tab 250mcg

Accord-UK Ltd has informed us of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D code, the status of packs may report as ‘EXPORT.' Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
1063015Digoxin Tab 250mcgAccord UK LtdXDG396

For stock control enquiries please contact Accord-UK Ltd Customer Services Team on 0800 373573.

For medical information enquiries please contact Accord-UK Ltd Medical Information Department on 01271 385257.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

29th July 2020

Class 2 Recall on Abstral Tab 200mcg (Schedule 2 CD)

Kyowa Kirin Limited is recalling the above batch as a precautionary measure, due to the reports of double tablets in a single blister pocket. This was identified during reference sample inspection and there is a potential low risk of accidental double dosage.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3460375ABSTRAL TAB 200MCG (SCHEDULE 2 CD)KYOWA KIRIN608777302

As this product is a Schedule 2 Controlled Drug. Please ensure that these returns are sent back with the Alliance Healthcare driver, who will have a ‘Specialist Product Recall Book' with them on Thursday 30th and Friday 31st July for completion and product uplift AM ONLY. If you have recalled products to return, please have this prepared in a bag for the driver to uplift. Due to Covid 19, the driver will complete the form on your behalf. They will ask for the quantity of stock you have to return and the name of the pharmacist. The driver will give you a copy of the completed form for your records. Please use our Returns Portal from Saturday 1st August for any additional returns related to this recall or alternatively call Customer Service for authorisation to return

Further Information

For Stock control enquiries please contact: Stuart Hay, Commercial Director Telephone: +44 (0) 1896 664045 Mobile: +44 (0) 7968 983286 E-mail: Stuart.Hay@kyowakirin.com For Medical information enquiries please contact:

Medical Information Direct Line: + 44 (0)1896 664 000 E-mail: medinfo@kyowakirin.com For Quality information please contact: Martin Smith (Responsible Person)

Telephone: +44 7904671807 E-mail: Martin.Smith@kyowakirin.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

23rd July 2020

Class 3 Recall on Irinotecan Vial 20mg/Ml

Accord Healthcare Limited is recalling the above batch as a precautionary measure, due to the observation of precipitation in the solution in the same batch marketed in another country (Malta). No complaints or adverse reaction reports have been received by the company to date for the UK product.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
1216860Irinotecan Vial 20mg/MlAccord HealthcareX21343
1123835Irinotecan Vial 20mg/MlAccord HealthcareX21343

For more information or medical information queries, please contact:Medinfo-BST Tel: 01271 385257 E-mail: medinfo@accord-healthcare.com

For stock control queries, please contact: Accord-UK Ltd Customer Services Team Tel: 0800 373573 E-mail: customerservices@accord-healthcare.com Fax: 01271 346106

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

23rd July 2020

Class 4 Caution in Use on Ecalta 100mg Powder For Concentrate For Solution For Infusion

Pfizer Limited has informed us that the packs for the above batches have not been packaged with the current version of the Patient Information Leaflet (PIL) containing updated storage instructions of the infusion solution in section 5.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3523594ECALTA 100MG PWD FOR CONC (IV)PFIZER LTDDN 6937
DX 1158

Further Information

For suspected adverse reaction and/or medical information queries, please contact: Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS Telephone: 01304 616 161

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This is a caution in use only we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

20th July 2020

Class 4 Caution in Use on Ibuprofen 200mg And 400mg Tablets

Aspar Pharmaceuticals Limited has informed us that the Patient Information Leaflets (PILs) within the ibuprofen packs below are missing some information identified from post-marketing experience that should be documented in Section 3 (How To Take The Tablets) and Section 4 (Possible Side Effects) of the PIL.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
6835151IBUPROFEN TAB 200MGASPAR PHARMACEUTICALSPlease refer to link above
6835169IBUPROFEN TAB 200MGASPAR PHARMACEUTICALSPlease refer to link above
1000132IBUPROFEN TAB 200MGASPAR PHARMACEUTICALSPlease refer to link above
1038892IBUPROFEN TAB 200MGASPAR PHARMACEUTICALSPlease refer to link above
1077601IBUPROFEN TAB 200MGASPAR PHARMACEUTICALSPlease refer to link above
1187509IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above
6835177IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above
6835185IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above
1058262IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above
1130509IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above
1130491IBUPROFEN TAB 400MGASPAR PHARMACEUTICALSPlease refer to link above

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This is a caution in use only and therefore we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

20th July 2020

Class 4 Caution in Use on Trimogal 100mg And 200mg Tablets

Ennogen Pharma Limited has informed us that the Patient Information Leaflets (PILs) within the packs for the affected batches below contain an error in Section 3 (How To Take Trimogal Tablets) with regard to the dosage instructions for children under 6 years.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
Alliance do not stockTRIMOGAL 100MG TABLETSENNOGEN PHARMA1402264
1402265
1402266
Alliance do not stockTRIMOGAL 200MG TABLETSENNOGEN PHARMA1402171
1402262
1402263

This is a caution in use only and we do not stock this line therefore we are not accepting stock returns. />
For more information or medical information queries, please contact:Ennogen Pharma Ltd Email: Info@Ennogen.com Tel: 01322 629 220.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

If you have any questions, then please contact your local Service Centre Customer Services team.